Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex Inc. (ZYXI) is a leader in non-invasive medical technology, specializing in electrotherapy devices, pain management solutions, and advanced patient monitoring systems. This news hub provides investors and industry professionals with essential updates on the company’s latest developments, regulatory milestones, and strategic initiatives.
Access real-time information on Zynex’s FDA clearances, product innovations, and financial performance. Our curated news collection covers earnings reports, partnership announcements, clinical trial outcomes, and market expansion efforts. Stay informed about developments across Zynex Medical’s therapeutic devices, Monitoring Solutions’ cardiac technologies, and Neurodiagnostics’ advancements in neurological care.
This resource is designed for those tracking Zynex’s progress in bringing clinically validated medical devices to market. Discover updates on key focus areas including TENS therapy improvements, laser-based monitoring innovations, and compliance with global medical standards. Bookmark this page for streamlined access to press releases, analyst insights, and objective reporting on Zynex’s role in shaping healthcare technology.
Zynex, a medical technology company listed under Nasdaq: ZYXI, has announced it will report its first-quarter financial results for 2023 on April 27, 2023. The report will include insights into their non-invasive medical devices for pain management and rehabilitation. Management will discuss the results during a conference call and webcast scheduled for 2:15 PM MT / 4:15 PM ET. Interested participants can register via the provided link or dial in.
Founded in 1996, Zynex specializes in developing and selling medical devices used in hospitals and patient care. The company emphasizes its forward-looking statements regarding future conditions and the inherent uncertainties involved.
Zynex, Inc. (NASDAQ: ZYXI) reported preliminary results for Q1 2023, showcasing significant growth in the pain management division. Orders reached a record high, up 61% from Q1 2022. Revenue estimates for the quarter are projected between $39.0 million and $41.0 million, reflecting a 29% increase from the previous year. The company maintains its full-year guidance, forecasting revenue of $180 million to $200 million and earnings per share between $0.40 and $0.50. Seasonal trends in the healthcare industry affect Q1 revenues, aligning with historical patterns. CEO Thomas Sandgaard emphasized strong sales momentum and growth potential as the company expands its market presence.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
